PDE9A and cardiovascular disorder: By the mid-2010s, these landmark findings—from the enzyme’s molecular characterization to its unique regulation of the NO-independent NP–cGMP pathway in failing hearts—established PDE9A as a promising therapeutic target for cardiovascular diseases.